Abstract
Integrins have emerged as modulators of a variety of cellular functions. They have been implicated in cell migration, survival, normal and aberrant cellular growth, differentiation, gene expression, and modulation of intracellular signal transduction pathways.
In this review article, the structural and functional characteristics of integrins, their expression and their potential role in prostate cancer metastases will be discussed.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Hynes RO: Cell adhesion: Old and new questions. Trends Cell Biol 9: M33–M37, 1999
Ruoslahti E: Integrins as signaling molecules and targets for tumor therapy. Kidney Int 51: 1413–1417, 1997
Byzova TV, Rabbani R, D’Souza SE, Plow EF: Role of integrin αvβ3 in vascular biology. Thromb Haemost 80: 726–734, 1998
Zheng DQ, Woodard AS, Tallini G, Languino LR: Substrate specificity of αvβ3 integrin-mediated cell migration and PI 3-kinase/AKT pathway activation. J Biol Chem 275: 24565–24574, 2000
Hemler ME, Weitzman JB, Pasqualini R, Kawaguchi S, Kassner PD, Berdichevsky FB: Structure, biochemical properties, and biological functions of integrin cytoplasmic domains. In: Takada Y (ed) Integrins: The Biological Problems. CRC Press Inc., Boca Raton, 1995, pp 1–35
Fornaro M, Languino LR: Alternatively spliced variants: A new view of the integrin cytoplasmic domain. Matrix Biol 16: 185–193, 1997
Williams MJ, Hughes PE, O’Toole TE, Ginsberg MH: The inner world of cell adhesion: Integrin cytoplasmic domains. Trends Cell Biol 4: 109–112, 1994
Vidal F, Aberdam D, Miquel C, Christiano AM, Pulkkinen L, Uitto J, Ortonne J-P, Menegnzzi G: Integrin β4 mutations associated with junctional epidermolysis bullosa with pyloric atresia. Nat Genet 10: 229–234, 1995
Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR: p27kip1 acts as a downstream effector of and is coexpressed with the β1C integrin in prostatic adenocarcinoma. J Clin Invest 103: 321–329, 1999
Patriarca C, Alfano RM, Sonnenberg A, Graziani D, Cassani B, de Melker A, Colombo P, Languino LR, Fornaro M, Warren WH, Coggi G, Gould VE: Integrin laminin receptor profile of pulmonary squamous cell and adenocarcinomas. Hum Pathol 29: 1208–1215, 1998
Manzotti M, Dell’Orto P, Maisonneuve P, Fornaro M, Languino LR, Viale G: Down-regulation of β1C integrin in breast carcinomas correlates with high proliferative fraction, high hislological grade, and larger size. Am J Pathol 156: 169–174, 2000
Perlino E, Lovecchio M, Vacca RA, Fornaro M, Moro L, Ditonno P, Battaglia M, Selvaggi FP, Mastropasqua MG, Bufo P, Languino LR: Regulation of mRNA and protein levels of β1 integrin variants in human prostate carcinoma. Am J Pathol 157: 1727–1734, 2000
Belkin AM, Retta SF, Pletjushkina OY, Balzac F, Silengo L, Fassler R, Koteliansky VE, Burridge K, Tarone G: Muscle β1D integrin reinforces the cytoskeleton-matrix link: Modulation of integrin adhesive function by alternative splicing. J Cell Biol 139:1583–1595, 1997
Retta SF, Balzac F, Ferraris P, Belkin AM, Fassler R, Humphries MJ, De Leo G, Silengo L, Tarone G: β1-integrin cytoplasmic subdomains involved in dominant negative function. Mol Biol Cell 9: 715–731, 1998
Fornaro M, Steger CA, Bennett AM, Wu JJ, Languino LR: Differential role of β1C and β1A integrin cytoplasmic variants in modulating focal adhesion kinase, protein kinase B/AKT, and Ras/Mitogen-activated protein kinase pathways. Mol Biol Cell 11: 2235–2249, 2000
Bottazzi ME, Assoian RK: The extracellular matrix and mitogenic growth factors control G1 phase cyclins and cyclin-dependent kinase inhibitors. Trends Cell Biol 7: 348–352, 1997
Frisch SM, Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol 9: 701–706, 1997
Schwartz MA, Schaller MD, Ginsberg MH: Integrins: Emerging paradigms of signal transduction. Annu Rev Cell DevBio 11:549–599, 1995
Holly SP, Larson MK, Parise LV: Multiple roles of integrins in cell motility. Exp Cell Res 261: 69–74, 2000
Parise LV, Lee J, Juliano RL: New aspects of integrin signaling in cancer. Semin Cancer Biol 10: 407–414, 2000
Ruoslahti E, Reed JC: Anchorage dependence, integrins and apoptosis. Cell 77: 477–478, 1994
Assoian RK, Schwartz MA: Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 11: 48–53, 2001
Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA: Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci USA 97: 10026–10031, 2000
Qiang YW, Kitagawa M, Higashi M, Ishii G, Morimoto C, Harigaya K: Activation of mitogen-activated protein kinase throughα5β1 integrin is required for cell cycle progression of B progenitor cell line, Reh, on human marrow stromal cells. Exp Hematol 28: 1147–1157, 2000
Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Koltz LH, Slingerland M: Loss of cyclin-dependent kinase inhibitor p27kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58: 542–548, 1998
Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE: Low P27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941–945, 1998
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat Med 3: 227–230, 1997
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222–226, 1997
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231–234, 1997
Cheville J, Lloyd R, Sebo T, Cheng L, Erickson L, Bostwick D, Lohse C, Wollan P: Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 11: 324–328, 1998
Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM: Levels of expression of p27KIP1 protein in human prostate and prostate cancer: An immunohistochemical analysis. Mod Pathol 12: 751–755, 1999
Fernandez PL, Arce Y, Farre X, Martinez A, Nadal A, Rey MJ, Peiro N, Campo E, Cardesa A: Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 187: 563–566, 1999
Fornaro M, Tallini G, Bofetiado CJM, Bosari S, Languino LR: Down-regulation of β1C integrin,aninhibitor of cell proliferation, in prostate carcinoma. Am J Pathol 149: 765–773, 1996
Fornaro M, Manzotti M, Tallini G, Slear AE, Bosari S, Ruoslahti E, Languino LR: β1C integrin in epithelial cells correlates with a nonproliferative phenotype: Forced expression of β1C inhibits prostate epithelial cell proliferation. Am J Pathol 153: 1079–1087, 1998
Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR: Prostatic carcinoma cell migration via α,β3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59: 1655–1664, 1999
Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE: Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem (19 Suppl): 232–237, 1994
Trikha M, Cai Y, Grignon D, Honn KV: Identification of a novel truncated αIIb integrin. Cancer Res 58: 4771–4775, 1998
Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE: Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 146: 1498–1507, 1995
Allen MV, Smith GJ, Juliano R, Maygarden SJ, Mohler JL: Downregulation of the β4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum Pathol 29:311–318, 1998
Davis TL, Cress AE, Dalkin BL, Nagle RB: Unique expression pattern of the α6β4 integrin and laminin-5 in human prostate carcinoma. Prostate 46: 240–248, 2001
Bonkhoff H, Stein U, Remberger K: Differential expression of α6 and α2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: Simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol 24: 243–248, 1993
Bonkhoff H: Analytical molecular pathology of epithelialstromal interactions in the normal and neoplastic prostate. Analyt Quant Cytol Histol 20: 437–442, 1998
Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ: Coordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33: 263–271, 1997
Hao J, Jackson L, Calaluce R, McDaniel K, Dalkin BL, Nagle RB: Investigation into the mechanism of the loss of laminin5 (α3β3γ2) expression in prostate cancer. Am J Pathol 158: 1129–1135, 2001
Hemler M, Mannion B, Berditchevski F: Association of TM4SF proteins with integrins: Relevance to cancer. Biochim Biophys Acta 1287: 67–71, 1996
Augustus M, Moul JW, Srivastava S: The Molecular Phenotype of the Malignant Prostate, IOS Press, Washington DC, 1999
Burton JL, Oakley N, Anderson JB: Recent advances in the histopathology and molecular biology of prostate cancer. BJU Int 85: 87–94, 2000
Guan JL, Trevithick JE, Hynes RO: Fibronectin/integrin interaction induces tyrosine phosphorylation of a 120 kDa protein. Cell Regul 2: 951, 1991
Kornberg L, Earp H, Turner C, Prockop C, Juliano R: Signal transduction by integrins: Increased protein tyrosine phosphorylation caused by clustering in β1 integrins. Proc Natl Acad Sci USA 88: 8392–8396, 1991
Schaller MD: Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540: 1–21, 2001
Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T, Alzawa S: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377: 539–543, 1995
Ilic D, Kanazawa S, Furuta Y, Yamamoto T, Aizawa S: Impairment of mobility in endodermal cells by FAK deficiency. Exp Cell Res 222: 298–303, 1996
Gary LA, Chang JF, Guan J-L: Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn J Cell Sci 109: 1787–1794, 1996
Gilmore A, Romer H: Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell 7: 1209–1224, 1996
Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S: Focaladhesionkinase pp125FAK expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 68: 164–171, 1996
Stanzione R, Picascia A, Chieffi P, Imbimbo C, Palmieri A, Mirone V, Staibano S, Franco R, De Rosa G, Schlessinger J, Tramontano D: Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Invest 81: 51–59, 2001
Sieg DJ, Hauck CR, Schlaepfer DD: Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci 112: 2677–2691, 1999
Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P: Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 18: 2459–2471, 1999
Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT: Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20:1152–1163, 2001
Keely P, Parise L, Juliano R: Integrins and GTPases in tumor cell growth, motility and invasion. Trends Cell Biol 8: 101–106, 1998
Rameh LE, Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274: 8347–8350, 1999
Jiang BH, Aoki M, Zheng JZ, Li J, Vogt PK: Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci USA 96: 2077–2081, 1999
Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, Walsh K, Sessa WC: Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 86: 892–896, 2000
Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J: Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16: 2783–2793, 1997
King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS: Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol 17: 4406–4418, 1997
Chen H-C, Guan J-L: Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase, Proc Natl Acad Sci USA 91: 10148–10152, 1994
Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262–267, 1998
Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431–437, 2001
Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 20: 1981–1989, 2001
Mercurio AM, Rabinovitz I, Shaw LM: The α6β4 integrin and epithelial cell migration. Curr Opin Cell Biol 13: 541–545, 2001
Maehama T, Dixon JE: PTEN: A tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9: 125–128, 1999
Tamura M, Gu J, Tran H, Yamada KM: PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 91: 1820–1828, 1999
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading and focal adhesions by tumor suppressor PTEN. Science 280: 1614–1617, 1998
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947, 1997
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of acandidate tumour suppressor gene, MMAC1, at chromosome 1023.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362, 1997
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997–5000, 1997
Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS: Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58: 204–209, 1998
Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S. Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA, et al.: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221–5225, 1997
Vlietstra RJ, van Alewijk DCJG, Hermans KGL, van Steenbrugge GJ, Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58: 2720–2723, 1998
McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR; Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291–4296, 1999
Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ: Increasing complexity of Ras signaling. Oncogene 17: 1395–1413, 1998
Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180–186, 1997
Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37–40, 2001
Clark E, Hynes R: Ras activation is necesary for integrin-mediated activation of extracellular signal-regulated kinase 2 and cytosolic phospholipase A2 but not for cytoskeletal organization. J Biol Chem 271:14814–14818, 1996
Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG: The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell 87: 733–743, 1996
Mainiero F, Murgia C, Wary KK, Curatola AM, Pepe A, Blumemberg M, Westwick JK, Der CJ, Giancotti FG: The coupling of α6β4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. EMBO J 16: 2365–2375, 1997
Miranti CK, Ohno S, Brugge JS: Protein kinase C regulated integrin-induced activation of the extracellular regulated kinase pathway upstream of Shc. J Biol Chem 274: 10571–10581, 1999
Schlaepfer DD, Hunter T: Integrin signalling and tyrosine phosphorylation: Just the FAKs? Trends Cell Biol 8: 151–157, 1998
Howe A, Aplin AE, Alahari SK, Juliano RL: Integrin signaling and cell growth control. Curr Opin Cell Biol 10: 220–231, 1998
Schwartz MA, Assoian RK: Integrins and cell proliferation: Regulation of cyclin-dependentkinases viacytoplasmic signaling pathways. J Cell Sci 114: 2553–2560, 2001
Sastry SK, Lakonishok M, Wu S, Truong TQ, Huttenlocher A, Turner CE, Horwitz AF: Quantitative changes in integrin and focal adhesion signaling regulate myoblast cell cycle withdrawal. J Cell Biol 144: 1295–1309, 1999
Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, Yamada KM: Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 146: 389–403, 1999
Cheresh DA, Leng J, Klemke RL: Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol 146: 1107–1116, 1999
Frisch SM, Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 13: 555–562, 2001
Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E: The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell 11: 1103–1112, 2000
Rosen K, Rak J, Leung T, Dean NM, Kerbel RS, Filmus J: Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol 149:447–456, 2000
Cho SY, Klemke RL: Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol 149: 223–236, 2000
Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279–284, 1999
Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M: Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 76: 37–51, 1997
Price DT, Rocca GD, Quo C, Ballo MS, Schwinn DA, Luttrell LM: Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162: 1537–1542, 1999
Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440–442, 1988
Reed JC: Mechanisms of apoptosis. Am J Pathol 157:1415–1430, 2000
Zhang Z, Vuori K, Reed JC, Ruoslahti E: The α5β1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92:6161–6165, 1995
Matter ML, Ruoslahti E: A signaling pathway from the α5β1 and αVβ3 integrins that elevates bcl-2 transcription. J Biol Chem 276: 27757–27763, 2001
Bruckheimer EM, Gjertsen BT, McDonnell TJ: Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 26: 382–398, 1999
Colombel M, Symmans F, Gil S, O’Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390–400, 1993
Del Bufalo D, Biroccio A, Leonetti C, Zupi G: Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 11: 947–953, 1997
Knox JD, Cress AE, Clark V, Manriquez L, Affinito KitSahn, Dalkin BL, Nagle RB: Differential expression of extracellular matrix molecules and the α6-integrins in the normal and neoplastic prostate. Am J Pathol 145: 167–174, 1994
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Fornaro, M., Manes, T., Languino, L.R. (2002). Integrins and prostate cancer metastases. In: Cher, M.L., Raz, A., Honn, K.V. (eds) Prostate Cancer: New Horizons in Research and Treatment. Developments in Oncology, vol 81. Springer, Boston, MA. https://doi.org/10.1007/0-306-48143-X_12
Download citation
DOI: https://doi.org/10.1007/0-306-48143-X_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7352-6
Online ISBN: 978-0-306-48143-7
eBook Packages: Springer Book Archive